Last update :
18/04/2024
InfoStab
Infostab
List of drugs
List of drugs
Summary lists
Summary lists
Search for compatibilities
Search for compatibilities
Y-site compatibility table
Y-site compatibility table
References
References
Research teams
Research teams
Valistab
Valistab
Poster
Poster
Links
Links
Sponsors
Sponsors
Authors
Authors
User’s guide
User’s guide
Newsletter
Newsletter
Anticancer drug   Bortezomib  
Injection
Stability in solutions Stability of mixtures Factors which affect stability Compatibility Route of administration References Pdf
   Chemical structure  

Tradename   Tradename     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers
Bemoncaz Mexico
Bicavan Chile
Biemib Turkey
Bomib Mexico
Borater Argentina
Borcade Turkey
Bormib Argentina
Bortezomib New Zealand
Bortezun Ecuador
Bortrac Ecuador, Peru
Bortzo Peru
Botemib Chile, Ecuador, Peru
Bozix Chile, Peru
Bozob Argentina, Ecuador, Peru
Bromadene Argentina
Egybort India
Elomaziv Mexico
Gysatri Argentina
Miasoma Argentina
Mibor Peru
Multizom Argentina
Rebtik Chile
Velcade Argentina, Australia, Austria, Belgium, Canada, Chile, Colombia, Denmark, Egypt, Finland, France, Germany, Great Britain, Greece, Hungary, Iceland, Ireland, Italy, Japan, Luxembourg, Malaysia, Mexico, Netherlands, New Zealand, Norway, Poland, Portugal, Romania, Saudi Arabia, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, United States of America, Venezuela
Velcord Peru
Vortemyel Romania
Zefra Argentina
Zegomib Romania
Zuricade Mexico
Stability in solutions   Injection   Stability in solutions : Bortezomib     
Container Solvent Concentration Temperature Storage Duration of stability References
Glass Sodium chloride 0,9% 1 mg/ml 2-6°C Protect from light
10 Day
3337
Level of evidence B
Glass Sodium chloride 0,9% 1 mg/ml 2-8°C Protect from light
28 Day
4137
Level of evidence A+
Glass Sodium chloride 0,9% 1 mg/ml 23°C Light
42 Day
2232
Level of evidence A
Glass Sodium chloride 0,9% 1 mg/ml 25°C Protect from light
7 Day
4137
Level of evidence A+
Glass Sodium chloride 0,9% 1 mg/ml 28°C Protect from light
8 Day
3337
Level of evidence B
Glass Sodium chloride 0,9% 1 mg/ml 4°C Protect from light
28 Day
2011
Level of evidence D
Glass Sodium chloride 0,9% 1 mg/ml 4°C Protect from light
42 Day
2232
Level of evidence A
Glass Sodium chloride 0,9% 1 mg/ml 4°C Protect from light
7 Day
3190
Level of evidence D
Glass Sodium chloride 0,9% 1 mg/ml 5°C Protect from light
5 Day
2010
Level of evidence A
Conflicting data
Glass Sodium chloride 0,9% 1 & 2.5 mg/ml 25°C Light
8 Hour
1911
Manufacturer's stability data
Glass Sodium chloride 0,9% 1 & 2.5 mg/ml 25°C Protect from light
25 Day
4485
Level of evidence A
Glass Sodium chloride 0,9% 1 & 2.5 mg/ml 4°C Protect from light
35 Day
4485
Level of evidence A
Glass Sodium chloride 0,9% 2,5 mg/ml 2-8°C Protect from light
21 Day
3688
Level of evidence B
Glass Sodium chloride 0,9% 2,5 mg/ml 2-8°C Protect from light
28 Day
4137
Level of evidence A+
Glass Sodium chloride 0,9% 2,5 mg/ml 23°C Light
21 Day
3688
Level of evidence B
Glass Sodium chloride 0,9% 2,5 mg/ml 25°C Protect from light
33 Day
3418
Level of evidence D
Glass Sodium chloride 0,9% 2,5 mg/ml 25°C Protect from light
7 Day
4137
Level of evidence A+
Glass Sodium chloride 0,9% 2,5 mg/ml 4°C Protect from light
30 Day
3349
Level of evidence B
Glass Sodium chloride 0,9% 2.5 mg/ml 2-8°C Not specified
14 Day
3537
Level of evidence D
Polypropylen Syringe Sodium chloride 0,9% 1 mg/ml 2-6°C Protect from light
10 Day
3337
Level of evidence B
Polypropylen Syringe Sodium chloride 0,9% 1 mg/ml 2-8°C Protect from light
35 Day
3240
Level of evidence A
Polypropylen Syringe Sodium chloride 0,9% 1 mg/ml 2-8°C Protect from light
28 Day
4137
Level of evidence A+
Polypropylen Syringe Sodium chloride 0,9% 1 mg/ml 22°C Light
3 Day
2010
Level of evidence A
Conflicting data
Polypropylen Syringe Sodium chloride 0,9% 1 mg/ml 25°C Protect from light
14 Day
3240
Level of evidence A
Polypropylen Syringe Sodium chloride 0,9% 1 mg/ml 25°C Protect from light
7 Day
4137
Level of evidence A+
Polypropylen Syringe Sodium chloride 0,9% 1 mg/ml 5°C Protect from light
5 Day
2010
Level of evidence A
Conflicting data
Polypropylen Syringe Sodium chloride 0,9% 1 & 2.5 mg/ml 25°C Protect from light
25 Day
4485
Level of evidence A
Polypropylen Syringe Sodium chloride 0,9% 1 & 2.5 mg/ml 4°C Protect from light
35 Day
4485
Level of evidence A
Polypropylen Syringe Sodium chloride 0,9% 2,5 mg/ml 2-8°C Protect from light
21 Day
3688
Level of evidence B
Polypropylen Syringe Sodium chloride 0,9% 2,5 mg/ml 2-8°C Protect from light
28 Day
4137
Level of evidence A+
Polypropylen Syringe Sodium chloride 0,9% 2,5 mg/ml 23°C Light
21 Day
3688
Level of evidence B
Polypropylen Syringe Sodium chloride 0,9% 2,5 mg/ml 25°C Protect from light
7 Day
4137
Level of evidence A+
Polypropylen Syringe Sodium chloride 0,9% 2,5 mg/ml 4°C Protect from light
23 Day
3418
Level of evidence D
Polypropylen Syringe Sodium chloride 0,9% 2.5 mg/ml 2-8°C Not specified
14 Day
3537
Level of evidence D
Polypropylen Syringe Sodium chloride 0,9% 2.5 mg/ml 2-8°C Protect from light
30 Day
3447
Level of evidence B
Syringe polycarbonate Sodium chloride 0,9% 2.5 mg/ml 2-8°C Protect from light
30 Day
3447
Level of evidence B
  Mentions Légales